glp-1 agonists and sglt2 inhibitors combination Effect of treatment with glucagon-like peptide-1 receptor sodium-glucose cotransporter-2 on incidence of cardiovascular and serious renal events: population based cohort study Combination therapy with SGLT2 inhibitors
Description
Recent expert consensus from 20232025 characterizes these medications as metabolic disease modifiers rather than simple glucose lowering agents
Berlin-Chemie and Roche (speakers bureau)
Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes
Data Availability Statement There are no data underlying this work.
However, despite the anti-diabetic and anti-obesity functions, of these dual and triple agonists, the long-term safety, cardiovascular, and renal benefits of these multi-target therapies need further validation
At that stage the impact of liraglutide on weight loss was fairly small, averaging a few percent per person (Mller, Preker)
